Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
2 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Esophageal Diseases"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting A Study of DKN-01 in Combination With Paclitaxel
Conditions: Esophageal Neoplasms;   Adenocarcinoma of the Gastroesophageal Junction;   Gastroesophageal Cancer;   Squamous Cell Carcinoma
Interventions: Drug: DKN-01;   Drug: Paclitaxel
2 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Breast Carcinoma;   Carcinoma of Unknown Primary Origin;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Carcinoma;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
To Top

† Indicates status has not been verified in more than two years